RESEARCH MONOGRAPH · KDC-MN-256

Propranolol

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

90/100

The original beta-blocker thats still the cleanest tool for separating peripheral from central adrenergic effects

Look, propranolol earned its keep. James Black's 1962 ICI synthesis, Nobel prize work, and 60+ years of clinical use across hypertension, arrhythmias, migraine, essential tremor, performance anxiety, and post-traumatic memory reconsolidation. It's a non-selective beta-1/beta-2 antagonist with significant lipophilicity, which is exactly why it's still useful as a research tool: it crosses the blood-brain barrier where atenolol doesnt, which lets you ask questions about central versus peripheral adrenergic contributions to behavior that pure peripheral beta-blockers cant answer.

The memory reconsolidation work is where propranolol got interesting again. The Brunet group in Montreal and Schiller's work at NYU in the 2000s and 2010s established that beta-adrenergic blockade during memory retrieval can attenuate the emotional valence of fear memories on subsequent recall. The findings have replicated unevenly and the clinical application to PTSD is still under debate, but the basic finding that propranolol pre-retrieval changes the trajectory of an emotional memory is one of the more interesting pieces of human behavioral pharmacology of the last 25 years.

What we like as a research tool is the cleanness of the mechanism. Competitive antagonism at beta-adrenoceptors, well-characterized binding, predictable pharmacokinetics (with the caveat of significant first-pass metabolism and CYP2D6 polymorphism affecting clearance). The racemic clinical compound has a small amount of activity from the S-enantiomer at 5-HT1A, which is worth knowing for behavioral work.

What we dont like is that the popular discourse around propranolol for social anxiety overstates what it does. It blunts the peripheral cardiovascular signs of arousal (the tremor, the racing pulse) which is genuinely useful for performance situations, but the central anxiety experience isnt erased the way the lay framing suggests. The dissociation between peripheral and central effects is actually the scientifically interesting part.

Sourcing is excellent. Generic since the 80s, pharmacopoeial quality widely available, the hydrochloride salt is the standard. Pure enantiomer material costs more and is available for SAR work.

Established workhorse with the underappreciated angle being its utility in memory reconsolidation paradigms. Reliability is high, mechanism is textbook, safety is well-characterized after six decades. Still earning its place.

Evidence: 95
Mechanism: 95
Reliability: 90
Safety: 85
Sourcing: 95
Value: 90
Signal: 78
Staying power: 88

Plain-language summary Intrigue 73 / 100

Propranolol (Inderal) is the first commercially successful beta-blocker, developed by James Black at ICI and approved by the FDA in 1967. Black's work on it earned him the Nobel Prize and reshaped cardiovascular medicine. It blocks both subtypes of beta-adrenergic receptor, dampening the heart's response to adrenaline as well as the bronchial and metabolic effects. Beyond its many cardiovascular uses, it has a substantial second life in psychiatry and neurology: it is the standard prescription for performance anxiety (one or two tablets before public speaking blunts the heart-pounding and tremor without affecting cognition), is first-line for migraine prevention, and has been studied for trauma memory reconsolidation in PTSD. Lipophilic enough to cross into the brain, which contributes to both its therapeutic and side effects. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Non-selective beta-adrenergic antagonist

A non-selective beta-adrenergic antagonist; the first beta-blocker, repurposed for performance anxiety and migraine prophylaxis.

Abstract

Propranolol (1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol; CAS 525-66-6; molecular formula C16H21NO2; molecular weight 259.34) is a non-selective beta-adrenergic antagonist developed by James Black at ICI and approved by the FDA in 1967 under the trade name Inderal. The compound is the first commercially successful beta-blocker, foundational to modern cardiovascular pharmacology. Beta-1 affinity is approximately equal to beta-2 affinity (non-selective). Plasma half-life is 3 to 6 hours; the lipophilic structure produces high CNS penetration, distinguishing propranolol from hydrophilic beta-blockers (atenolol, nadolol) for indications requiring central effect. Approved indications include hypertension, angina, atrial fibrillation, migraine prophylaxis, essential tremor, and hypertrophic cardiomyopathy. Off-label use is extensive: performance anxiety (most common psychiatric indication), PTSD memory reconsolidation, akathisia, hyperthyroid tachycardia. The 5-HT receptor partial agonism (weak) was a former curiosity but is not clinically meaningful at standard doses. Used as the canonical non-selective beta-blocker reference compound.

Mechanism of action

Non-selective beta-1 and beta-2 adrenergic antagonism. Lipophilic with high CNS penetration; weak 5-HT receptor partial agonism (clinically minor).

Reported research dose ranges

Clinical 10 to 320 mg in the published literature. Performance anxiety 10 to 40 mg PRN. Rodent studies 1 to 30 mg/kg.

References

Black JW, et al. A new adrenergic beta-receptor antagonist. Lancet 1964.
Brunet A, et al. Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res 2008.
Tindall RS. Propranolol in essential tremor. Drugs 1981.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-256

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Propranolol

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs